Treating CA LEMS in Small Cell Lung Cancer: Amifampridine, Immunomodulatory Therapy, and ICI Safety Considerations

Dr. Primdahl details amifampridine (Firdapse), FDA-approved in 2018 for CA LEMS based on 2 randomized placebo-controlled studies demonstrating clinically meaningful functional improvement with a favorable safety profile. The drug was subsequently approved for patients aged 6 years and older. As a potassium channel blocker, amifampridine prolongs presynaptic action potentials, enhances calcium influx, and increases acetylcholine release, directly targeting CA LEMS pathophysiology. Practical dosing begins at 5 to 10 mg three times daily, titrated up to a maximum of approximately 80 mg per day. It outperforms pyridostigmine for CA LEMS symptom control. An important clinical goal in patients with SCLC receiving ICIs is achieving LEMS symptom control with amifampridine while avoiding steroids, which would counteract ICI mechanisms.

For acute exacerbations or crisis presentations, intravenous immunoglobulin (IVIG) is the go-to intervention. Steroids may be used as a bridge. Long-term immunosuppressants (thiopurines, cyclosporines) carry theoretical concerns about counteracting antitumor immune surveillance in SCLC, and data are limited; they are generally reserved for refractory cases requiring joint oncology-neurology decision-making. CA LEMS patients generally have a milder clinical course than those with myasthenia gravis and require escalation less often.

On ICI safety, Dr. Primdahl identifies this as a critical evidence gap: ICI use is not contraindicated in CA LEMS but requires close monitoring. Different paraneoplastic syndromes (notably anti-Hu versus CA LEMS) differ substantially in biology, course, and risk, and should not be managed identically. Prospective studies are urgently needed to define which patients can safely receive ICIs and how to monitor them, including an ongoing prospective study at Northwestern. NCCN ICI toxicity management guidelines provide a starting framework but were not designed for this specific population.